Standard BioTools Files 8-K on Operations and Financial Condition

TL;DR

**Standard BioTools just dropped an 8-K on its operations and financials, keeping the market in the loop.**

AI Summary

Standard BioTools Inc. filed an 8-K on February 28, 2024, reporting on Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits. The filing indicates the company's current business address as 2 Tower Place, Suite 2000, South San Francisco, California 94080, with a business phone number of (650) 266-6000. This report was filed under the Securities Exchange Act of 1934.

Why It Matters

This filing provides an update on Standard BioTools' financial and operational status, offering transparency to investors and the market regarding its current performance and disclosures.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial and operational conditions, not indicating any immediate high-risk events.

Key Players & Entities

• Standard BioTools Inc. (company) — Registrant
• February 28, 2024 (date) — Date of earliest event reported and filing date
• 2 Tower Place, Suite 2000, South San Francisco, California 94080 (location) — Principal executive offices
• (650) 266-6000 (phone_number) — Registrant's telephone number
• 001-34180 (other) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob

Filing Documents

• lab-20240228.htm (8-K) — 46KB
• lab-ex99_1.htm (EX-99.1) — 672KB
• 0000950170-24-022060.txt ( ) — 895KB
• lab-20240228.xsd (EX-101.SCH) — 51KB
• lab-20240228_htm.xml (XML) — 5KB

02 - Results of Operations and Financial Condition

Item 2.02 - Results of Operations and Financial Condition On February 28, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2023. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading "Outlook for 2024" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information set forth under the heading "Outlook for 2024" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Standard BioTools Inc., dated February 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 28, 2024 STANDARD BIOTOOLS INC. By: /s/ Jeffrey Black Name: Jeffrey Black Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR